Canterbury DHB

Context

Prognosis and Management of CEL-NOS

Patients rarely respond to imatinib or interferon α.

Prognosis is variable, but generally thought to be poor, and transformation to acute leukemia is common. One small series6 gave median survival of 22.2 months.

Adverse risk factors include:

About this Canterbury DHB document (537415):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

August 2018

Next Review:

April 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 537415